No Response to First Antifungals Tied to Worse Keratitis Outcomes

This article originally appeared here.
Share this content:
No Response to First Antifungals Tied to Worse Keratitis Outcomes
No Response to First Antifungals Tied to Worse Keratitis Outcomes

MONDAY, July 11, 2016 (HealthDay News) -- Fungal keratitis patients pretreated with antifungal medication appear to have worse outcomes, according to a study published online June 21 in Clinical & Experimental Ophthalmology.

Catherine Q. Sun, M.D., from the University of California, San Francisco, and colleagues conducted a randomized , double-blind trial to determine the optimal treatment for filamentous fungal keratitis. Patients at the Aravind Eye Care System in India were randomized to treatment with either topical natamycin or voriconazole.

The researchers found that 44 percent of the 323 patients enrolled presented on an antifungal agent. Larger mean baseline infiltrate size and epithelial defect size were seen in pretreated patients. Pretreatment was associated with significantly worse three-month visual acuity, larger three-month scar size, and increased odds of corneal perforation and/or transplant in multivariate analysis.

"Fungal keratitis that is smear-positive despite being pretreated with appropriate antifungal agents appears to be a risk factor for worse outcomes, likely due to initial ulcer severity and treatment failure," conclude the authors.

The drugs used in the study were donated by Alcon and Pfizer.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

USPSTF Urges Abuse Screening for Reproductive-Aged Women

USPSTF Urges Abuse Screening for Reproductive-Aged Women

Evidence lacking for assessing balance of benefits, harms of screening for abuse of seniors, vulnerable

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Five-Day Nitrofurantoin Beats Single-Dose Fosfomycin for UTI

Increased likelihood of clinical and microbiological resolution for uncomplicated UTI in women

Exercise Intervention Doesn't Improve Walking Ability in PAD

Exercise Intervention Doesn't Improve Walking Ability in PAD

Smaller mean change from baseline to follow-up in 6-minute walking distance with exercise intervention

is free, fast, and customized just for you!

Already a member?

Sign In Now »